Harvard’s Wyss Institute for Biologically Inspired Engineering, Brigham and Women’s Hospital, the Mayo Clinic and MIT now describe a new class of hydrogel-based embolic agents. Their study, published in Science Translational Medicine, provides proof-of-concept and first preclinical evidence in animal models that the shear-controlled hydrogel can be delivered by catheters and injected into blood vessels to form robust and safe blockages.
